0.00Open0.10Pre Close0 Volume1 Open Interest10.00Strike Price0.00Turnover238.20%IV44.57%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.0343Delta0.0118Gamma178.60Leverage Ratio-0.0280Theta-0.0002Rho-6.13Eff Leverage0.0021Vega
MediWound Stock Discussion
MediWound Delivers Record Revenue Growth: NexoBrid Sales Soar 42% Amid Major Funding Wins
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
Tuesday, 17th December at 8:00 am
YAVNE, Israel, Dec. 17, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced it will host a virtual Key Opinion Leader (KOL) event on Wednesday, January 8, 2025, at 10:00 AM ET. T...
·3 mins ago
Mediwound Announces U.S. Food and Drug Administration Approval of Nexobrid® for the Treatment of Pediatric Patients With Severe Thermal Burns
No comment yet